FAQ: What Do the New Federal Medical Cannabis Dispensary Registrations Mean for Patients?

Americans for Safe Access Explains the Justice Department's Historic Announcement of More Than 900 Federal Dispensary Registrations

On October 30, 2026, the U.S. Department of Justice announced that the Drug Enforcement Administration (DEA) is moving forward with federal registrations for more than 900 state-licensed medical cannabis dispensaries across seven states. The announcement marks a major milestone in implementing the new federal regulatory framework for qualifying medical cannabis activities under Schedule III.

For medical cannabis patients, this is a historic achievement as we approach the 30th anniversary of California's Proposition 215, the nation's first statewide medical cannabis law. The federal government is formally recognizing and registering the dispensaries that patients fought to establish, building on three decades of patient advocacy and state medical cannabis programs.

Americans for Safe Access (ASA) has prepared the following frequently asked questions to explain what this development means for patients, caregivers, healthcare professionals, and state medical cannabis programs. The answers also address what remains unresolved and the opportunities ahead for strengthening patients' rights and establishing a comprehensive national medical cannabis program.

The Justice Department announced that DEA is moving forward with the initial issuance of federal registrations for more than 900 state-licensed medical cannabis dispensaries. These registrations are being issued under the Attorney General's April 2026 order, which established a federal regulatory framework for qualifying medical cannabis activities under Schedule III of the Controlled Substances Act.

For decades, dispensaries operating legally under state medical cannabis laws generally could not obtain federal authorization to dispense cannabis. The new framework allows qualifying state-licensed dispensaries to become federally registered businesses, subject to DEA oversight and applicable federal requirements, including security, recordkeeping, and inventory controls.

These are not 900 newly opened dispensaries. They represent federal recognition of qualifying state medical cannabis operations, marking a significant transition from federal nonrecognition of these programs to their inclusion in the federal regulatory system.

Medical cannabis dispensaries are the foundation of patient access in state medical cannabis programs. Patients and their advocates spent nearly 30 years establishing and defending these systems while federal law continued to classify cannabis as a Schedule I substance.

Federal registration recognizes the access infrastructure that patients helped establish and allows the federal government to build on existing state programs rather than requiring patients and states to abandon what they have created. It also provides an important foundation for establishing a comprehensive national approach to medical cannabis access and regulation.

As ASA Founder and Executive Director Steph Sherer explained:

"For the first time, the federal government is recognizing and registering the medical cannabis dispensaries that patients fought to establish. This is a tremendous victory for patient access and an opportunity to build on 30 years of progress."

The initial registrations cover medical cannabis dispensaries in Alabama, Florida, Mississippi, South Dakota, Texas, Virginia, and West Virginia. These states have established medical cannabis licensing systems, although their approaches to regulating dispensaries, manufacturers, and patient enrollment vary considerably.

DEA has indicated that it will continue processing applications and issuing registrations to qualifying businesses through a phased process. The initial announcement does not establish a timeline for registration in other states, and additional federal guidance may be needed to address differences among state regulatory systems.

The first round of more than 900 registrations is an encouraging indication of participation in the new federal framework. Based on available state data, the seven states collectively have roughly 1,100 medical cannabis dispensing locations, although state reporting methods differ and some states distinguish between business licenses, authorized dispensing locations, and operating dispensaries.

Florida alone has nearly 800 medical cannabis dispensing locations, while Mississippi has approximately 175 to 200 licensed or operating dispensaries. We do not yet know how many eligible dispensaries applied, how many applications remain pending, or whether every federal registration corresponds to a separately counted state dispensing location.

The announcement therefore does not establish the percentage of eligible dispensaries that have received federal registration. Nevertheless, the substantial number of registrations in the initial phase provides reason for optimism about the ability of existing state medical cannabis programs to participate in federal regulation.

Qualifying medical cannabis products and activities covered by the Attorney General's April 2026 order are regulated under Schedule III of the Controlled Substances Act. This represents a significant change from the previous federal framework, which generally treated cannabis activity conducted under state medical cannabis programs as Schedule I activity.

However, the order does not provide blanket federal legalization of cannabis. Activities outside its defined scope remain subject to Schedule I controls, and the broader proposal to reschedule cannabis remains under consideration through a separate federal administrative proceeding.

Federal registration also does not authorize adult-use cannabis sales or automatically permit patients to transport cannabis across state lines. Patients and businesses must continue following applicable federal and state requirements, including restrictions that remain in place under the new framework.

For most patients, the announcement does not require an immediate change in how they obtain their medicines. Patients should continue using dispensaries authorized under their state medical cannabis programs and complying with applicable requirements for patient registration, healthcare provider certifications, and purchasing limits.

Federal registration does not automatically replace state medical cannabis programs or eliminate existing patient enrollment requirements. Patients should maintain their medical cannabis identification cards, certifications, and other documentation, particularly as states and federal agencies establish procedures for distinguishing qualifying medical activity from adult-use activity.

Patients who want to know whether their dispensary has received federal registration can contact the dispensary or their state medical cannabis regulator. As implementation continues, ASA will monitor developments that could affect patient access and provide updates as additional federal guidance becomes available.

No. Federal scheduling, DEA registration, and FDA drug approval are separate regulatory processes, and registration of a dispensary does not mean that the cannabis products it sells have received FDA approval.

The announcement also does not automatically replace existing state medical cannabis recommendation or certification systems with a federal prescription requirement. Patients should continue following their state program's rules and working with their healthcare providers while federal agencies clarify how the new framework will operate.

Federal recognition of medical cannabis dispensaries creates important opportunities to advance patients' rights and protections. For decades, patients have faced discrimination involving employment, housing, healthcare, education, and other essential services because they use cannabis medicines recommended by their healthcare providers.

The new federal framework provides a basis for reviewing policies developed when cannabis was treated entirely as a Schedule I substance. However, federal registration does not automatically guarantee employment accommodations, hospital access, housing protections, or other rights, and the legal protections available to individual patients continue to depend on the circumstances and applicable laws.

ASA has expanded its longstanding Patients' Rights Campaign to the federal level to help patients and caregivers understand these changes, assert applicable legal protections, request individualized consideration, and document discrimination. The campaign also seeks to identify outdated institutional policies and encourage federal agencies to clarify how existing protections apply to medical cannabis patients.

Patients can learn more and access practical resources through ASA's Federal Patients' Rights Campaign.

This is one of the most important unanswered questions about the new federal registration process. Six of the seven states included in the initial announcement have medical-only cannabis programs, while Virginia allows adult-use possession but has not yet implemented regulated adult-use retail sales.

Many other states have integrated medical and adult-use cannabis programs, allowing businesses to operate under both types of licenses or share facilities, inventory systems, and supply chains. Patients in these states may depend on dispensaries that also serve adult-use customers, making it essential that federal registration procedures accommodate existing medical access systems.

ASA hopes DOJ and DEA will work closely with state regulators to develop practical pathways for businesses holding both medical and adult-use licenses, including regulatory flexibility where legally permissible. States may also need to adjust licensing structures or establish additional procedures to distinguish federally qualifying medical cannabis activity from adult-use activity.

The objective should be to preserve and strengthen the access patients already have while allowing qualifying medical cannabis businesses to participate in federal regulation. Federal registration should provide new opportunities for patient access without requiring states to dismantle or unnecessarily complicate the medical programs patients depend on.

States play a central role in determining how successfully the new federal framework can be implemented. In June 2026, ASA released State Preparedness for Federal Cannabis Regulation & Enforcement, outlining recommendations to help governors, legislators, and regulators prepare existing medical cannabis programs for federal oversight while protecting patient access.

These recommendations include helping qualified businesses navigate DEA registration, preserving medical cannabis supply chains, strengthening patient enrollment, and establishing procedures for verifying qualifying medical activity. States with combined medical and adult-use programs may need additional adjustments to licensing, inventory tracking, and patient verification systems to accommodate federal requirements.

Although DOJ and DEA establish federal registration requirements, states remain responsible for their own licensing and regulatory systems. Coordination between federal agencies and state regulators will be essential to preserving access, avoiding unnecessary disruptions, and extending the benefits of federal recognition to additional medical cannabis programs.

Read more about ASA's State Preparedness Recommendations.

DEA has stated that it will continue reviewing applications and issuing registrations to qualifying dispensaries through a phased process. The agency is also reviewing applications from manufacturers and distributors that supply medical cannabis dispensaries, with additional requirements involving facility inspections, production controls, and quota determinations.

Under the Attorney General's order, qualifying businesses that applied during the initial 60-day period and whose applications remain pending may continue certain medical cannabis transactions with other qualified applicants and newly registered entities, subject to the order's requirements. These provisions are intended to support continuity during implementation but do not provide blanket federal authorization for every state-licensed cannabis business.

State licensure alone does not automatically grant federal registration or establish eligibility under the order. Businesses should review DEA's official registration requirements and seek qualified regulatory guidance when determining how the new framework applies to their operations.

Federal registration does not automatically lower the price of medical cannabis or require private insurers, Medicare, or Medicaid to cover state medical cannabis products. The announcement also does not establish new federal pricing requirements or eliminate the financial barriers that many patients experience when obtaining their medicines.

The new federal framework may create opportunities to address longstanding regulatory and financial challenges as medical cannabis becomes more integrated into federal healthcare policy. ASA believes that improving affordability and establishing appropriate pathways for insurance coverage must be part of the next phase of medical cannabis reform, alongside stronger product safety standards and patient protections.

Federal registration is a major step toward establishing a national medical cannabis framework, but important differences among state programs remain. Patients continue to face varying eligibility requirements, product availability, costs, and legal protections depending on where they live, while questions involving interstate access, insurance coverage, research, and healthcare integration remain unresolved.

ASA's proposed Medical Cannabis & Cannabinoid Act (MCCA) offers a legislative pathway to build on federal progress by establishing a new Schedule VI for cannabis and cannabinoids and creating an Office of Medical Cannabis and Cannabinoid Control within the Department of Health and Human Services. This framework would provide a comprehensive approach to patient access, product safety, research, healthcare integration, and patient protections, drawing on the experience of existing state programs.

With the November 3 elections approaching, ASA's Compassionate Candidate Campaign also provides candidates from every political party an opportunity to publicly state their commitments to federal medical cannabis legislation and congressional oversight. The next Congress will have an opportunity to build on the progress achieved through federal registration while addressing the remaining gaps in national medical cannabis policy.

Learn more about ASA's Medical Cannabis & Cannabinoid Act and the Compassionate Candidate Campaign.

Patients should continue following their state medical cannabis requirements and maintaining current registrations, healthcare provider certifications, and other documentation of their medical status. As additional federal registrations are issued, patients can monitor updates from their state regulators, dispensaries, and ASA to understand how implementation may affect their access.

Patients who experience discrimination involving medical cannabis should document the circumstances, request written explanations of relevant institutional policies, and review the legal protections that may apply to their situation. ASA's Federal Patients' Rights Campaign provides resources for understanding changing laws, requesting appropriate consideration, and identifying policies that may need to be updated.

Patients and caregivers can also share experiences and concerns with ASA to help identify barriers to access as the federal framework develops. These experiences will help inform ASA's continued work with state regulators, federal agencies, healthcare institutions, and Congress to ensure that patient needs remain central to implementation.

Visit ASA's Federal Patients' Rights Campaign for additional information and resources.

Thirty Years of Patient Progress. The Work Continues.

The federal government's recognition of more than 900 medical cannabis dispensaries is a historic achievement for the patients who worked to establish state medical cannabis programs. It demonstrates that federal regulation can build on decades of state experience and patient advocacy while creating opportunities to strengthen oversight, improve protections, and expand the role of medical cannabis within the U.S. healthcare system.

As the 30th anniversary of California's Proposition 215 approaches on November 5, this announcement provides an opportunity to recognize how far medical cannabis policy has progressed. ASA will continue working with patients, states, federal agencies, healthcare professionals, and Congress to ensure that federal recognition translates into lasting patient access, stronger protections, and a comprehensive national medical cannabis program.

Read the Justice Department's October 30 announcement for additional details on the federal registration process. You can also support ASA's work to protect patients' rights and advance medical cannabis policy.

Prepared by Americans for Safe Access. This FAQ provides general educational information and does not replace individualized legal or medical advice.